Eur Rev Med Pharmacol Sci 2019; 23 (24): 10776-10784

DOI: 10.26355/eurrev_201912_19780

Long non-coding RNA OIP5-AS1 promotes proliferation of gastric cancer cells by targeting miR-641

L.-W. Wang, X.-B. Li, Z. Liu, L.-H. Zhao, Y. Wang, L. Yue

Department of Gastrointestinal Surgery, Zhoukou Central Hospital, Zhoukou, China. qiuzhiwonder@163.com


OBJECTIVE: Long non-coding RNAs (lncRNAs) have emerged as pivotal regulators of various tumors. Currently, lncRNA OPI5-AS1 (OPI5-AS1) has been identified as a tumor suppressor gene involved in several cancers. Therefore, the aim of this study was to investigate the function of OPI5-AS1 in gastric cancer (GC) progression.

PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to detect the expressions of OPI5-AS1 and microRNA-641 (miR-641) in tissues and cells. The Cell Counting Kit-8 (CCK-8), colony formation, and 5-Ethynyl-2′-deoxyuridine (EDU) assays were used to verify the effect of OPI5-AS1 on cell proliferation. Cell cycle distribution was detected by flow cytometry. Furthermore, Western blot was performed to detect the protein expressions of cyclin D1 and p-AKT.

RESULTS: OPI5-AS1 was significantly upregulated, while miR-641 was downregulated in GC tissues and cells. OPI5-AS1 expression was remarkably inversely correlated with miR-641 in GC. Moreover, OPI5-AS1 could sponge miR-641 and regulate its expression in GC cells. Functional experiments showed that OPI5-AS1 overexpression remarkably accelerated GC cell proliferation and cell cycle. However, miR-641 overexpression could reverse the functional effects induced by OPI5-AS1 overexpression.

CONCLUSIONS: OPI5-AS1 overexpression promotes tumorigenesis and development of GC by sponging miR-106a-5p. In addition, our findings suggest that OPI5-AS1 may serve as an innovative and prospective therapeutic target for GC.

Free PDF Download

To cite this article

L.-W. Wang, X.-B. Li, Z. Liu, L.-H. Zhao, Y. Wang, L. Yue
Long non-coding RNA OIP5-AS1 promotes proliferation of gastric cancer cells by targeting miR-641

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 24
Pages: 10776-10784
DOI: 10.26355/eurrev_201912_19780